Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer

Stage III nonsmall cell lung cancer (NSCLC) encompasses a heterogeneous group of patients, some of whom may be candidates for potentially curative surgery, although for the majority surgery is not an option. Recommended therapy for patients with unresectable stage III disease is concurrent treatment...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Huber, Rudolf M. (VerfasserIn) , Reck, Martin (VerfasserIn) , Thomas, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: September 30, 2013
In: The European respiratory journal
Year: 2013, Jahrgang: 42, Heft: 4, Pages: 1119-1133
ISSN:1399-3003
DOI:10.1183/09031936.00143112
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1183/09031936.00143112
Verlag, lizenzpflichtig, Volltext: https://erj.ersjournals.com/content/42/4/1119
Volltext
Verfasserangaben:Rudolf M. Huber, Martin Reck and Michael Thomas
Beschreibung
Zusammenfassung:Stage III nonsmall cell lung cancer (NSCLC) encompasses a heterogeneous group of patients, some of whom may be candidates for potentially curative surgery, although for the majority surgery is not an option. Recommended therapy for patients with unresectable stage III disease is concurrent treatment with chemotherapy and thoracic radiotherapy, although even with this dual modality therapy survival remains disappointing. Novel classes of agents including targeted therapies have been shown to improve survival in advanced stage NSCLC, raising the possibility that these agents may have benefits in multimodal therapy when combined with chemoradiotherapy. Here we consider the rationale for combining new agents with chemoradiotherapy and the evidence from clinical studies assessing multimodal strategies for the management of patients with unresectable stage III NSCLC. - Tweetable abstract ERSpublications - click to tweetThe rationale for combining new agents with chemoradiotherapy to treat stage III NSCLC and data from clinical studies http://ow.ly/nuE1d
Beschreibung:Gesehen am 02.11.2021
Beschreibung:Online Resource
ISSN:1399-3003
DOI:10.1183/09031936.00143112